RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000144.xml
Zeitschrift für Orthomolekulare Medizin 2017; 15(02): 7-18
DOI: 10.1055/s-0043-113077
DOI: 10.1055/s-0043-113077
Wissen
Krebs: Mikronährstoffe in der onkologischen Intervention
Weitere Informationen
Publikationsverlauf
Publikationsdatum:
14. Juli 2017 (online)
![](https://www.thieme-connect.de/media/OM/201702/lookinside/thumbnails/10-1055-s-0043-113077-1.jpg)
Summary
Aktuelle Studien weisen darauf hin, dass der labordiagnostisch validierte und therapieangepasste Einsatz von Mikronährstoffen ein wichtiger Baustein supportiver und komplementäronkologischer Therapiekonzepte ist. Die optimale Versorgung mit Nahrungsenergie sowie antientzündlichen und immunstabilisierenden Mikronährstoffen wie Selen, L-Carnitin, Vitamin C und D steigert das Ansprechen auf antineoplastische Therapien und verringert die Nebenwirkungsrate. Lebensqualität und Prognose der Patienten können verbessert werden.
-
Literatur
- 1 Bray F, Jemal A, Grey N. et al. Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol 2012; 13: 790-801
- 2 American Cancer Society Global Cancer: Facts and Figures. 3. Aufl. New York: American Cancer Society; 2015
- 3 Gröber U. Antioxidants and other micronutrients in complementary oncology. Breast Care 2009; 4 (01) 13-20
- 4 Ströhle A, Zänker K, Hahn A. Nutrition in oncology: the case of micronutrients. Oncol Rep 2010; 24 (04) 815-828
- 5 Gröber U, Holzhauer P, Kisters K. et al. Micronutrients in Oncological Intervention. Nutrients 2016; 8 (03) 163
- 6 Gröber U, Hübner J, Holzhauer P, Kleeberg UR. Antioxidanzien und andere Mikronährstoffe in der komplementären Onkologie. Onkologe 2010; 16: 73-79
- 7 Micke O, Bruns F, Glatzel M. et al. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. European Journal of Integrative Medicine 2009; 1: 22-30
- 8 D’Andrea G. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 2005; 55 (05) 319-321
- 9 Block KI. et al. Impact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence from randomized controlled trials. Cancer Treat Rev 2007; 33 (05) 407-418
- 10 Block KI. et al. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008; 123 (06) 1227-1239
- 11 Mücke R, Schomburg L, Büntzel J. et al. Komplementärer Seleneinsatz in der Onkologie. Der Onkologe, 2010; 16: 181-186
- 12 Gröber U. Arzneimittel und Mikronährstoffe. 3. Aufl. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2014
- 13 Tong H, Isenring E, Yates P. The prevalence of nutrition impact symptoms and their relationship to quality of life and clinical outcomes in medical oncology patients. Support Care Cancer 2009; 17 (01) 83-90
- 14 Bozzetti F. SCRINIO Working Group Screening the nutritional status in oncology: a preliminary report on 1,000 outpatients. Support Care Cancer 2009; 17 (03) 279-284
- 15 Holzhauer P, Gröber U. Titel Der Gynäkologe 2016; Volume: Seitenzahl
- 16 Fakih M. Anti-EGFR monoclonal antibody-induced hypomagnesaemia. Lancet Oncol 2007; 8 (05) 366-367
- 17 Vickers MM, Karapetis CS, Tu D. et al. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Ann Oncol. 2013; 24 (04) 953-960
- 18 Knijn N, Tol J, Koopman M. et al. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 2011; 47 (03) 369-374
- 19 Chen P, Wang L, Li H. et al. Incidence and risk of hypomagnesemia in advanced cancer patients treated with cetuximab: A meta-analysis. Oncol Lett 2013; 5 (06) 1915-1920
- 20 McDonnell SL, Baggerly C, French CB. et al. Serum 25-Hydroxyvitamin D Concentrations ≥40 ng/ml Are Associated with > 65 % Lower Cancer Risk: Pooled Analysis of Randomized Trial and Prospective Cohort Study. PLoS One 2016; 11 (04) e0152441
- 21 Gröber U, Kisters K. Influence of drugs on vitamin D and calcium metabolism. Dermatoendocrinol 2012; 4 (02) 158-166
- 22 Gröber U, Spitz J, Reichrath J. et al. Vitamin D: Update 2013: From rickets prophylaxis to general preventive healthcare. Dermatoendocrinol 2013; 5 (03) 331-347
- 23 Fink M. Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. J Clin Oncol 2011; 29 (04) e81-e82
- 24 Prieto-Alhambra D, Javaid MK, Servitja S. et al. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospectiv cohort study. Breast Cancer Res Treat 2011; 125 (03) 869-878
- 25 Khan QJ, Reddy PS, Kimler BF. et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119 (01) 111-118
- 26 Favus MJ. Bisphosphonates for osteoporosis. N Engl J Med 2010; 363 (21) 2027-2035
- 27 Carmel AS, Shieh A, Bang H, Bockman RS. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥ 33 ng/ml. Osteoporos Int 2012; 23 (10) 2479-2487
- 28 Berruti A, Cook R, Saad F. et al. Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration. Oncologist 2012; 17 (05) 645-652
- 29 Bedogni A, Saia G, Bettini G. et al. Osteomalacia: the missing link in the pathogenesis of bisphosphonate-related osteonecrosis of the jaws?. Oncologist 2012; 17 (08) 1114-1119
- 30 Bergman P, Sperneder S, Höijer J. et al. Low vitamin d levels are associated with higher opioid dose in palliative cancer patients – results from an observational study in sweden. PLoS One 2015; 10 (05) e0128223
- 31 Dev R, Del Fabbro E, Schwartz GG. et al. Preliminary report: vitamin D deficiency in advanced cancer patients with symptoms of fatigue or anorexia. Oncologist 2011; 16 (11) 1637-1641
- 32 Khan QJ, Reddy PS, Kimler BF. et al. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 2010; 119 (01) 111-118
- 33 Bittenbring JT, Neumann F, Altmann B. et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 2014; 32 (29) 3242-3248
- 34 Gröber U, Holick MF. Vitamin D: Die Heilkraft des Sonnenvitamins. 3., vollst. überarb. und erweiterte Aufl. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2015
- 35 Gröber U, Holzhauer P, Kisters K. Besser durch die Krebstherapie. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2014
- 36 Bellinger F P, Raman AV, Reeves MA, Berry MJ. Regulation and function of selenoproteins in human disease. Biochem J 2009; 422: 11-22
- 37 Wallenberg M, Misra S, Wasik AM. et al. Selenium induces a multi-targeted cell death process in addition to ROS formation. J. Cell Mol Med 2014; 18: 671-684
- 38 Wallenberg M, Misra S, Björnstedt M. Selenium cytotoxicity in cancer. Basic Clin Pharmacol Toxicol 2014; 114: 377-386
- 39 Dennert G, Zwahlen M, Brinkman M. et al. Selenium for preventing cancer. Cochrane Database Syst Rev 2011; (05) CD005195 doi: 10.1002/14651858.CD005195
- 40 Vinceti M, Dennert G, Crespi CM. et al. Selenium for preventing cancer. Cochrane Database Syst Rev. 2014; (03) CD005195 doi: 10.1002/14651858.CD005195.pub3
- 41 Brodin O, Eksborg S, Wallenberg M. et al. Pharmacokinetics and toxicity of sodium selenite in the treatment of patients with carcinoma in a phase I clinical trial: The SECAR Study. Nutrients 2015; 7: 4978-4994
- 42 Son H, Lee SM, Yoon RG. et al. Effect of selenium supplementation for protection of salivary glands from iodine-131 radiation damage in patients with differentiated thyroid cancer. Hell J Nucl Med 2017; 20 (01) 62-70
- 43 Khasabova IA. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci 2012; 32 (20) 7091-7101
- 44 Visovsky C. et al. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin JOncol Nurs 2007; 11 (06) 901-913
- 45 Sun Y. et al. A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine ALC) in treatment of chemotherapy-induced peripheral neuropathy (CPIN). J Clin Oncol 2012; 30: abstr 9017 (symptom management/supportivecare/palliativecare)
- 46 Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with firstline chemotherapy in two cases of ovarian cancer. J Am Coll Nutr 2003; 22: 118-123
- 47 Drisko J A, Chapman J, Hunter VJ. The use of antioxidant therapies during chemotherapy. Gynecol Oncol 2003; 88: 434-439
- 48 Vollbracht C, Schneider B, Leendert V. et al. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: Results of a retrospective, multicentre, epidemiological cohort study in Germany. Vivo 2011; 25: 983-990
- 49 Welsh J L, Wagner B A, van’t Erve. et al. Pharmacological ascorbate with gemcitabine for the control of metastastic and node-positive pancreatic cancer (PACMAN): Results from a phase I clinical trial. Cancer Chemother Pharmacol 2013; 71: 765-775
- 50 Monti DA, Mitchell E, Bazzan AJ. et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS ONE 2012; 7: e29794
- 51 Seo MS, Kim JK, Shim JY. High-dose vitamin C promotes regression of multiple pulmonary metastases originating from hepatocellular carcinoma. Yonsei Med J 2015; 56: 1449-1452
- 52 PDQ Cancer Complementary and Alternative Medicine Editorial Board High-Dose Vitamin C (PDQ): Health Professional Version. PDQ Cancer Information Summaries; National Cancer Institute; Bethesda, MD, USA: 2002–2015